(Q36802060)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1 reference

ChEBI release 2020-05-28

ChEBI ID

75246

hepatic encephalopathy

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Dong Wu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Shu-Mei Wu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jie Lu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ying-Qun Zhou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ling Xu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

3 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

Gastroenterology research and practice

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

236963

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

29 February 2020

copyright license

start time

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

A current review of the diagnostic and treatment strategies of hepatic encephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

29 September 2017

Hepatic encephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Pathogenesis and diagnosis of hepatic encephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Rifaximin treatment in hepatic encephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Rifaximin for the treatment of hepatic encephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Review article: the current pharmacological therapies for hepatic encephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Management of hepatic encephalopathy: role of rifaximin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Rifaximin: in vitro and in vivo antibacterial activity--a review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

The art of quality assessment of RCTs included in systematic reviews

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Correlation between ammonia levels and the severity of hepatic encephalopathy.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

5 September 2018

Hepatic Encephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3638683

Durability of rifaximin response in hepatic encephalopathy

5 September 2018

1 reference

12 December 2020

Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease

1 reference

12 December 2020

Hepatic encephalopathy

1 reference

12 December 2020

Assessment of low-grade hepatic encephalopathy: a critical analysis

1 reference

12 December 2020

Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure

1 reference

12 December 2020

Prognostic significance of hepatic encephalopathy in patients with cirrhosis

1 reference

12 December 2020

Liver disease, aminoglycoside antibiotics and renal dysfunction

1 reference

12 December 2020

Identifiers

DOI

10.1155/2013/236963

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

release_i2z7gkgvkvb73bgsgxocg7tj7u

29 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i2z7gkgvkvb73bgsgxocg7tj7u

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

23653636

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23653636%20AND%20SRC:MED&resulttype=core&format=json